CUAMC
SYRS

China Universal Asset Management Company’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

China Universal Asset Management Company’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-59
Closed – – 480
2022
Q3 		$0 Buy
+59
New +$479 ﹤0.01% 467

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

China Universal Asset Management Company's SYRS Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2022, closing a stake of 59 shares.

China Universal Asset Management Company first reported a position in SYRS in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 57 funds tracked by Wall St. Rank hold SYRS as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 59 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • China Universal Asset Management Company first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Syros Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q3 2022.
  • 57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.